Barclays reiterates an 'Overweight' on ARIAD Pharmaceuticals (ARIA); Why 3 Week PFS Increase May be Relevant
Tweet Send to a Friend
Barclays reiterates an 'Overweight' on ARIAD Pharmaceuticals (NASDAQ: ARIA), PT $9.
Barclays analyst says, "With focus on clinical relevance of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Barclays analyst says, "With focus on clinical relevance of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
